CCL2 News and Research

RSS

Olverembatinib a potent inhibitor of Omicron NTD-mediated cytokine release

Researchers determine whether mutations in the Omicron NTD influence its potential to stimulate myeloid cells and enhance inflammatory cytokine release.

22 May 2022

Natural immunity weak and short-lived in unvaccinated after Omicron infection

In a recent study posted to the journal Nature, researchers showed that the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron infection without SARS-CoV-2 vaccination conferred poor cross-variant neutralizing capacities.

20 May 2022

The different actions of CBD in SARS-CoV-2 infection

An article has described the role of cannabidiol as a potential inhibitor of hyperinflammation in SARS-CoV-2 infection.

29 Mar 2022

Tuberculosis infection protects mice against COVID-19

To study if prior Mtb infection affects the response to CoV2 infection, K18-hACE2 (ACE2) and C57BL/6 (B6) mice were infected with Mtb, and post thirty days, were exposed to CoV2.

27 Mar 2022

Elevated P2X7 receptor levels in COVID-19 patients correlate with disease severity

In a recent study posted to the bioRxiv preprint server, researchers demonstrated that the soluble P2X7 receptor is increased in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) patients. They also showed that the elevated P2X7 receptors correlated with coronavirus disease 2019 (COVID-19) severity.

9 Mar 2022

Dual therapeutic potential of zapnometinib against COVID-19

Researchers assessed the impact of the drug zapnometinib on human immune response against coronavirus disease 2019.

2 Mar 2022

Scientists identify multi-kinase inhibitors that can effectively block SARS-CoV-2-mediated cytokine release

Researchers investigated the efficacy of two multi-kinase inhibitors, olverembatinib and ponatinib, in inhibiting SARS-CoV-2 omicron-mediated cytokine release in human peripheral blood mononuclear cells.

10 Feb 2022

Attenuated tissue immune responses against SARS-CoV-2 in obese and non-obese patients

In a new study, researchers evaluated the single-cell transcriptomes from bronchiolar lavage in three adult cohorts comprising of obese and non-obese SARS-CoV-2 patients.

24 Jan 2022

Even mild SARS-CoV-2 respiratory-only infection can cause long-term neurologic damage

A new bioRxiv* preprint study led by Michelle Monje of Stanford University in California finds that a mild COVID-19 infection can produce long-term neurological damage. Persistent cognitive complications are one of many symptoms of long COVID, and the latest results suggest the severity of COVID-19 induced brain fog is similar to cancer’s “chemobrain.”

16 Jan 2022

Study identifies ORF8 protein as a key COVID-19 causing factor

New study suggests that the SARS-CoV-2 ORF8 protein is the underlying cause behind severe COVID-19 infection.

8 Dec 2021

Study shows SARS-CoV-2 can infect and replicate in human iPSC-derived neurons

In a study recently published on the bioRxiv preprint server, researchers attempted to further increase the scope of previous studies in examining SARS-CoV-2 infection of human CNS resident cells.

22 Nov 2021

Scientists identify new gene that contributes to type 1 diabetes progression

When the pro-inflammatory pair, a receptor called CCR2 and its ligand CCL-2, get together, it increases the risk of developing type 1 diabetes, scientists report.

16 Nov 2021

SARS-CoV-2 infection inhibited by CCR2 signaling

A new study discusses the role of monocytes in protecting individuals from SARS-CoV-2.

15 Nov 2021

Investigation of Budesonide's mechanism of action against SARS-CoV-2

Researchers look to gain an understanding of the mechanism of action of budesonide in improving the prognosis of patients with SARS-CoV-2 infection.

1 Nov 2021

Small molecule drug can attenuate the triggers of neuroinflammation, preclinical study shows

Neuroinflammation can worsen outcomes in stroke, traumatic brain injury, or spinal cord injury, as well as accelerate neurodegenerative diseases like ALS, Parkinson's, or Alzheimer's. This suggests that limiting neuroinflammation may represent a promising new approach to treat neurological diseases and neuropathic pain that are driven by neuroinflammation.

24 Sep 2021

Study points to a possible new approach for treating MRSA superbug

A study released in STEM CELLS Translational Medicine, by researchers at the Baker Institute for Animal Health, part of Cornell University's College of Veterinary Medicine, Ithaca, N.Y., details in a relevant ex vivo model how treating wounds with the secretion of a type of stem cell called mesenchymal stromal cell (MSC) effectively reduced methicillin-resistant Staphylococcus aureus – better known as MRSA viability and stimulated the surrounding skin cells to build up a defense against the bacterial invader.

16 Sep 2021

CD39+ monocyte count higher in pregnant than non-pregnant COVID-19 patients

A new study published on the bioRxiv* server describes the changes in the representation of a subset of activated monocytes in this group of patients.

23 Jun 2021

Ponatinib identified as a potent inhibitor of SARS-CoV2-induced cytokine storm

Researchers at the Human Biology Division, Fred Hutchinson Cancer Research Center in Washington, United States, found that the FDA-approved, multi-kinase inhibitor Ponatinib is a potent inhibitor of the N-terminal domain (NTD) -mediated cytokine storm. Ponatinib is an oral drug used for the treatment of chronic myeloid leukemia (CML).

14 Apr 2021

Male fetuses impair the maternal and placental immune response to SARS-CoV-2 infection in pregnancy, finds study

The ongoing COVID-19 pandemic, caused by SARS-CoV-2, is now established to be more likely to lead to symptomatic and serious illness in males relative to females. This may extend as far back as pregnancy, suggests a recent study.

31 Mar 2021

SARS-CoV-2 spike stimulates hyperinflammation via Toll-like receptor 2

A new study, released on the bioRxiv* preprint server, describes the mechanism of inflammation in severe COVID-19, besides revealing a potential new therapeutic target to modulate the severity of COVID-19.

19 Mar 2021